Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-01 · accession 0001415889-25-000621 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-03 | 2025-01-01+ | ACRS | Walker Neal | INTERIM CEO, Dir | F - Tax | $2.48 | -17.4K | 1.44M | -1% | -$43.2K |
| DM | 2025-01-03 | 2025-01-01+ | ACRS | Walker Neal | INTERIM CEO, Dir | M - OptEx | — | +38.6K | 1.47M | +3% | — |
| DM | 2025-01-03 | 2025-01-01+ | ACRS | Walker Neal | INTERIM CEO, Dir | M - OptEx | $0.00 | -38.6K | 37.9K | -50% | $0 |
| D | 2025-01-03 | 2025-01-02 | ACRS | Walker Neal | INTERIM CEO, Dir | A - Grant | $0.00 | +88.3K | 88.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | F | D | 13,532 | $2.48 | 1,454,810 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-01 | M | A | 9,467 | — | 1,443,097 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| 3 | Common | Common Stock | 2025-01-01 | F | D | 3,904 | $2.48 | 1,439,193 | D | — | — | |
| 4 | Common | Common Stock | 2025-01-02 | M | A | 29,149 | — | 1,468,342 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| 5 | Derivative | Restricted Stock Units | 2025-01-02 | M | D | 29,149 | $0.00 | 59,184 | D | — · — to — | 29,149 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. (F4) The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| 6 | Derivative | Restricted Stock Units | 2025-01-02 | A | A | 88,333 | $0.00 | 88,333 | D | — · — to — | 88,333 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. (F4) The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| 7 | Derivative | Restricted Stock Units | 2025-01-01 | M | D | 9,467 | $0.00 | 37,867 | D | — · — to — | 9,467 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. (F3) The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. |